Arvinas Förvaltning
Förvaltning kriterier kontrolleras 3/4
Arvinas VD är Randy Teel, utsedd i Feb 2026, har en mandatperiod på mindre än ett år. totala årliga ersättningen är $ 3.78M, bestående av 12.6% lön 87.4% bonusar, inklusive företagsaktier och optioner. äger direkt 0.073% av företagets aktier, värda $ 493.62K. Den genomsnittliga mandatperioden för ledningsgruppen och styrelsen är 2.3 år respektive 6.6 år.
Viktig information
Randy Teel
Verkställande direktör
US$3.8m
Total ersättning
| VD-lön i procent | 12.58% |
| Anställning som VD | less than a year |
| Ägande av VD | 0.07% |
| Ledningens genomsnittliga anställningstid | 2.3yrs |
| Styrelsens genomsnittliga mandatperiod | 6.6yrs |
Senaste uppdateringar av ledningen
Recent updates
ARVN: Early Neurology Readouts And Cash Runway Will Drive Bullish Repricing
Analysts have nudged Arvinas' implied price target higher by a few dollars per share, reflecting updated models after recent Q4 results, early approval for Vepdeg, and a fuller view of the upcoming data cycle for programs like ARV-102 and other 2026 readouts. Analyst Commentary Recent Street research on Arvinas clusters around early approval for Vepdeg, the updated Q4 models, and a more detailed path for ARV-102 and other 2026 data events.
ARVN: Upcoming Neurology Data Readouts Will Challenge Current Share Price Assumptions
Narrative Update on Arvinas Analysts have lifted their average price targets on Arvinas by several dollars per share, into a mid-teens to around $20 range. This reflects updated models after recent quarterly results, a busy calendar of expected ARV-102 data readouts across neurological indications, and views on the company’s multiyear cash runway.ARVN: 2026 Neurology Readouts And Cash Runway Will Drive Bullish Reassessment
Analysts have modestly raised the Arvinas fair value estimate from $14.56 to $14.88, reflecting higher Street price targets after recent Q4 model updates, expanded program timelines, and detailed cash runway assessments across multiple firms. Analyst Commentary Recent Street research presents a mixed but generally constructive picture for Arvinas, with several firms adjusting price targets higher following the Q4 update and program milestones.
ARVN: 2026 Neurology Readouts And Cash Runway Will Drive Future Upside
The analyst price target for Arvinas has moved from $18 to $21, with analysts pointing to updated models that reflect revised assumptions around revenue growth, profit margins, and future P/E as they factor in recent quarterly results and upcoming clinical data readouts. Analyst Commentary Recent research updates show a cluster of higher price targets on Arvinas, with bullish analysts pointing to refreshed models following quarterly results and upcoming clinical data.ARVN: 2026 Neurology Readouts And Cash Runway Will Balance Execution Risks
Narrative Update on Arvinas The analyst price target for Arvinas has moved higher by $1.75, with analysts tying their updated views to refreshed post earnings models, a higher fair value estimate of $14.56, and anticipated 2026 data readouts for ARV-102 and other pipeline programs. Analyst Commentary Recent research updates show a cluster of higher price targets on Arvinas, with analysts revising their models after the latest quarterly report and company updates.ARVN: New Leadership And Lymphoma Program Will Drive Future Upside
Analysts have maintained their $18.00 price target for Arvinas, with updated assumptions that reflect adjusted views on revenue growth, profit margins, and future P/E expectations. What's in the News Arvinas appointed Randy Teel, Ph.D., as Chief Executive Officer, effective February 12, 2026.ARVN: Hematology Data And Preclinical Combination Results Will Balance Cash Burn Risks
Analysts have nudged their price target on Arvinas slightly higher to about $12.81 from $12.75, citing updated assumptions around discount rates, revenue contraction, profit margins, and future P/E expectations. What's in the News Arvinas shared preclinical data for ARV-393, an investigational PROTAC BCL6 degrader, in combination with glofitamab at the 67th American Society of Hematology Annual Meeting and Exposition in Orlando, Florida (Key Developments).Companies Like Arvinas (NASDAQ:ARVN) Are In A Position To Invest In Growth
Jan 27
ARVN: New Hematology And KRAS Data Will Balance Cash Burn Risks
Narrative Update on Arvinas The analyst price target for Arvinas has moved slightly higher from US$12.44 to US$12.75. Analysts attribute this adjustment to updated assumptions for fair value, discount rate, profit margin, and future P/E.ARVN: Future Returns Will Balance Breast Cancer Setbacks And Cash Burn Risks
Analysts have nudged their price target for Arvinas slightly higher to about $12.44 from $12.31, while highlighting rising concerns that competitive progress in hormone receptor positive, HER2 negative metastatic breast cancer could leave vepdegestrant at risk of becoming less relevant and keep investor focus on cash burn. Analyst Commentary Bullish Takeaways Bullish analysts point to the updated average price target of about $12.44 as an indication that some on the Street still see room for upside relative to the most cautious views, even as competitive pressure builds around vepdegestrant.ARVN: Early Neuroscience Pipeline Will Drive Future Upside Despite Breast Cancer Reset
Analysts have sharply cut their price target on Arvinas to about $18 from over $60. The change reflects heightened competitive pressure on vepdegestrant, uncertainty around out-licensing timelines, and a reset of expectations toward the company’s earlier-stage oncology and neuroscience pipeline.ARVN: Refocus On Neuroscience And Cost Discipline Will Balance Risks And Opportunities
Analysts have revised Arvinas' price target lower. Notable cuts include Goldman's reduction to $6 from $8, reflecting heightened uncertainty around vepdegestrant's outlook and increased competitive pressures in breast cancer therapies.Arvinas: Approvable, But Asset Looks Mediocre, Initiating With A Hold Rating
Nov 24ARVN: Core Oncology And Neuroscience Focus Will Drive Share Recovery Ahead
Arvinas' analyst price target has been revised downward from approximately $17.44 to $12.31 per share. Analysts cite increased competitive risks for vepdegestrant along with heightened uncertainty surrounding the company's future commercial prospects.Precision Therapies Will Meet Demand Despite Clinical And Regulatory Risks
Arvinas’ consensus price target was reduced to $17.44, reflecting increased commercialization uncertainty for vepdegestrant following the decision to seek a third-party partner, restructuring, and delays to peak sales estimates despite ongoing support for the early-stage pipeline. Analyst Commentary Recent decision by Arvinas and Pfizer to seek a third-party partner for vepdegestrant has introduced significant uncertainty around commercialization timing and strategy, prompting downside risk to valuation.Improved Revenues Required Before Arvinas, Inc. (NASDAQ:ARVN) Stock's 26% Jump Looks Justified
Sep 09We're Not Very Worried About Arvinas' (NASDAQ:ARVN) Cash Burn Rate
Jun 01Arvinas, Inc.'s (NASDAQ:ARVN) Shares Bounce 37% But Its Business Still Trails The Industry
May 01
Phase III And PROTAC Data Will Advance Pipeline Despite Hurdles
Successful trials and partnerships in oncology could support Arvinas' transition to commercial operations, driving growth and revenue potential.Arvinas: Veritac-2 ITT Failure Confirms Limited Prospects
Mar 14Arvinas, Inc. (NASDAQ:ARVN) Not Doing Enough For Some Investors As Its Shares Slump 56%
Mar 12Arvinas' Vepdegestrant: Why The Data May Not Hold Up
Dec 25Arvinas (NASDAQ:ARVN) Is In A Good Position To Deliver On Growth Plans
Dec 24Investors Still Waiting For A Pull Back In Arvinas, Inc. (NASDAQ:ARVN)
Nov 28Arvinas: Major Catalyst Ahead, But Its History Gives Me Pause
Oct 16Arvinas, Inc. (NASDAQ:ARVN) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Aug 02Arvinas: Hugely Important Data Catalyst Upcoming - Success May Prove Elusive
Jul 12Here's Why We're Watching Arvinas' (NASDAQ:ARVN) Cash Burn Situation
Jun 27Arvinas: Behind The Huge Rally
Mar 03What Arvinas, Inc.'s (NASDAQ:ARVN) 28% Share Price Gain Is Not Telling You
Feb 25Analys av ersättningar till VD
| Datum | Total ersättning | Lön | Företagets resultat |
|---|---|---|---|
| Dec 31 2025 | n/a | n/a | -US$81m |
| Sep 30 2025 | n/a | n/a | -US$58m |
| Jun 30 2025 | n/a | n/a | -US$73m |
| Mar 31 2025 | n/a | n/a | -US$47m |
| Dec 31 2024 | US$4m | US$475k | -US$199m |
Ersättning vs marknad: Randy s total kompensation ($USD 3.78M ) är ungefär genomsnittet för företag av liknande storlek på US marknaden ($USD 3.69M ).
Ersättning vs inkomst: Otillräcklig data för att jämföra Randy s ersättning med företagets resultat.
VD OCH KONCERNCHEF
Randy Teel (45 yo)
less than a year
Anställning
US$3,776,333
Kompensation
Dr. Randy Teel, Ph.D. served as Interim Chief Financial Officer and Treasurer at Arvinas, Inc. since February 29, 2024 until April 2024 and served as its Chief Business Officer since April 2024 until Febru...
Ledningsgrupp
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| CEO, President & Director | less than a year | US$3.78m | 0.073% $ 493.6k | |
| CFO & Treasurer | 1.9yrs | US$3.72m | 0.026% $ 176.5k | |
| Chief Scientific Officer | 1.9yrs | US$2.97m | 0.063% $ 423.6k | |
| Chief Medical Officer | 2.2yrs | US$6.10m | 0.039% $ 260.2k | |
| VP & Chief Accounting Officer | no data | inga uppgifter | 0.014% $ 97.1k | |
| Vice President of Investor Relations | 5.3yrs | inga uppgifter | inga uppgifter | |
| General Counsel & Corporate Secretary | 2.3yrs | inga uppgifter | inga uppgifter | |
| Senior VP & Chief Human Resources Officer | no data | inga uppgifter | inga uppgifter | |
| Senior Vice President of Regulatory Affairs | 3.6yrs | inga uppgifter | inga uppgifter | |
| Chief Commercial Officer | no data | inga uppgifter | inga uppgifter | |
| Senior VP & Global Head of Oncology Strategy and Program Leadership | 3.2yrs | inga uppgifter | inga uppgifter |
2.3yrs
Genomsnittlig anställningstid
56yo
Genomsnittlig ålder
Erfaren ledning: ARVN s ledningsgrupp anses vara erfaren ( 2.3 års genomsnittlig anställningstid).
Styrelseledamöter
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| CEO, President & Director | less than a year | US$3.78m | 0.073% $ 493.6k | |
| Independent Director | 7.8yrs | US$451.53k | 0.082% $ 554.3k | |
| Member of Scientific Advisory Board | 6.6yrs | inga uppgifter | inga uppgifter | |
| Independent Director | 6.8yrs | US$451.53k | 0.016% $ 105.3k | |
| Chairman & Lead Director | 7.9yrs | US$480.39k | 0.13% $ 840.8k | |
| Independent Director | 6.5yrs | US$456.53k | 0.016% $ 105.3k | |
| Member of Scientific Advisory Board | 6.6yrs | inga uppgifter | inga uppgifter | |
| Member of Scientific Advisory Board | 6.6yrs | inga uppgifter | inga uppgifter | |
| Member of Scientific Advisory Board | 6.6yrs | inga uppgifter | inga uppgifter | |
| Independent Director | 5.9yrs | US$461.53k | 0.016% $ 105.3k | |
| Director | 8.7yrs | US$12.75m | 1.55% $ 10.4m | |
| Chairman of Scientific Advisory Board | 1.3yrs | US$4.22m | 0.18% $ 1.2m |
6.6yrs
Genomsnittlig anställningstid
63yo
Genomsnittlig ålder
Erfaren styrelse: ARVN s styrelse anses vara erfaren ( 6.6 års genomsnittlig mandatperiod).
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/03 01:12 |
| Aktiekurs vid dagens slut | 2026/05/01 00:00 |
| Intäkter | 2025/12/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Arvinas, Inc. bevakas av 28 analytiker. 17 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Peter Lawson | Barclays |
| Etzer Darout | Barclays |
| Tazeen Ahmad | BofA Global Research |